Imprivata Drug Diversion Intelligence

Detection is what the product is for and machine learning is named as the method in the vendor's own voice across product pages, a knowledge hub entry and a market expansion announcement, described as establishing baseline behavior and norms for medication access and flagging deviation from them. The OneRx medication name standardization component is also described as AI assisted, so models do work at two distinct points in the pipeline rather than one.

Still, a substantial part of what is sold alongside the model is conventional: more than 250 report types, an investigation case platform and an optional human monitoring services team, all of which would function on rules alone.

The system generates risk scores and alerts and does not act on them: Imprivata's Responsible AI Transparency Report says the AI requires human oversight and feedback to take action, that the customer configures its own risk tolerance, and that users see the factors and weighted features behind each score.

Flags route into an investigation platform built for case handling, with reporting for documentation, and an optional Imprivata monitoring services team exists for organizations without the capacity to work the queue. The oversight structure is described, then, with the thresholds set by the customer.

What is missing is what happens after a flag proves wrong: nothing describes how a score is corrected, whether the flagged person is told, or what qualification the person reviewing a flagged clinician needs.

The product page describes machine learning and behavioral analytics establishing baseline behavior for medication access, with deviation, peer comparison and out of hours access as signals, plus OneRx, AI assisted standardization of medication names across source systems.

The Responsible AI Transparency Report adds how the models are built: training on historical data using labeled datasets where possible, cross validation and hyperparameter tuning, evaluation on separate validation sets against named metrics, and explainability features that show the factors behind each risk score. The approach is clear; the version and update discipline behind it is not. No model family, training population, version, update practice or performance value is published for the detection model, so what the system does can be followed, but not how well it does it.

Only a general architecture is described. The Responsible AI Transparency Report explains that the models draw on electronic health record data, authoritative employee data, access logs and patient data, cleaned and anonymized before use, with algorithms selected per application, and the product page describes machine learning and behavioral analytics over dispensing activity plus the AI assisted OneRx name standardization.

No model provider, framework, host or third party component is named on the product page or in the report, and nothing distinguishes capability inherited from the FairWarning and Maize Analytics acquisitions from capability built or licensed since. The trust page's note that Imprivata applies AI assisted analysis in its own product security process concerns how the software is built, not what runs inside it.

Two drug diversion case studies dated January 2026 are published, from a 600 bed New York health system and a Mid Atlantic health system, neither named. The New York study reports that unresolved monthly discrepancies fell to below 5 percent after deployment, with the director of pharmacy quoted, and describes the six month selection process; the Mid Atlantic study describes the same kind of program improvement without a comparable figure.

The percentage is vendor reported, with no baseline, method or denominator, and the customers are not named. No outcome study, detection accuracy figure, false positive rate or independent evaluation is published for the diversion product, and the product page's claim that it protects staff from false accusations carries no figure behind it. Adoption is asserted as widespread in the United States, and a Canadian market entry was announced in March 2023, but neither is quantified.

Specific positions are published on retention and de identification. Retention: the product page states that controlled substance data is stored for three years to support tracking and auditing, and the published Business Associate Agreement commits Imprivata to return or destroy protected health information at the end of the services on the customer's request.

De identification: the Responsible AI Transparency Report says data is cleaned, anonymized and standardized before it is fed into a model, and the agreement reserves Imprivata's right to use de identified or aggregated information. What is not stated specifically is training use: the report says models are trained on historical data without saying whether one customer's data trains models used for others, or whether behavioral baselines are fitted per customer.

No safety engineering is published: the report lists limitations and says errors are promptly addressed and corrected, but nothing describes guardrails on the risk scoring or how a safety event is handled.

Imprivata publishes its Business Associate Agreement in full on its legal page. It is an agreement between the customer as covered entity and Imprivata, Inc. as business associate, and it takes effect for any customer installing Imprivata software, so it is readable before contracting and applies at every level of purchase.

It commits Imprivata to breach and security incident reporting, to HIPAA safeguards, to making its records available to the Secretary of Health and Human Services, and to returning or destroying protected health information at the end of the services, and it requires any agent or subcontractor that receives protected health information to agree to implement reasonable and appropriate safeguards. One term stands out: Imprivata keeps the right to use de identified or aggregated information and statistical information derived from customer data.

On a public trust and security page and in its Responsible AI Transparency Report, Imprivata names its certifications: ISO/IEC 27001:2022 and ISO/IEC 27701:2019 for its information security and privacy information management systems, covering the processing of personal and protected health information; SOC 2 Type 1 and Type 2 reports across the security, availability, processing integrity, confidentiality and privacy criteria; Cyber Essentials Plus in the United Kingdom; and a third party audit of its enterprise access product against the DEA's electronic prescribing rules.

None of them comes with an artifact that can be opened without a request. The scope is stated at company level and nothing enumerates which products sit inside the certified management systems or the SOC 2 reports, so whether Drug Diversion Intelligence is covered is not stated. The trust page also describes current practice, including the defensive use of AI assisted analysis in Imprivata's own product security and release process.

Positioned as monitoring and investigation software for compliance and pharmacy teams, Drug Diversion Intelligence makes no device claim and is scoped accordingly. It covers the controlled substance lifecycle and stores data for three years to support tracking and auditing.

Imprivata's Responsible AI Transparency Report says its healthcare AI assists professionals and is not intended to replace human decision making, and lists HIPAA, GDPR and the EU AI Act among the regimes it complies with. No statement of the company's regulatory position for this product is published, and nothing guides customers on how output should be used in reporting to the Drug Enforcement Administration or a state board of pharmacy, which is where these findings routinely end up.

Imprivata publishes a Responsible AI Transparency Report for its healthcare products, written for healthcare professionals, patients and regulators, and names an Artificial Intelligence Committee with a contact address. The report describes the data sources the models use, a development process running from anonymized preprocessing through feature engineering, algorithm selection, training on historical data and evaluation on separate validation sets, the metrics monitored (accuracy, precision, recall, F1 and area under the ROC curve), explainability features that show users the factors behind a risk score, stated limitations, and a commitment to identify and mitigate bias related to gender, ethnicity, socioeconomic status and other factors using fairness aware techniques.

The gap is that the report covers the whole portfolio: no metric value, subgroup result or bias evaluation is published for Drug Diversion Intelligence, and the product page's statement that the system protects staff from false accusations carries no false positive rate.

Imprivata states where responsibility sits and builds mechanisms to contest an output, and publishes nothing that stands behind the output itself. Its Responsible AI Transparency Report says the ultimate responsibility for decisions remains with the customer, who should use AI insights as one tool rather than the sole basis for a decision, that users can see the factors and weighted features behind a risk score, and that the customer configures its own risk tolerance.

The product routes flags into an investigation platform with case handling and reporting. Those are mechanisms to examine and challenge a flag before acting on it. The report's statement that errors are promptly addressed and corrected is not a commitment a customer can test, and nothing gives a flagged clinician a route to see or contest a score, although the product page says the system protects staff from false accusations. The mutual indemnity in the published Business Associate Agreement covers breaches of that agreement, not the accuracy of the analytics.

The product analyzes data from electronic health records, pharmacy management systems and dispensing systems, and reaches into electronic prescribing workflows, so the input surface spans clinical and pharmacy operations rather than dispensing cabinets alone. The existence of OneRx is itself indirect evidence of integration breadth, since a medication name normalization layer is only necessary across heterogeneous sources. No specific electronic health record or dispensing cabinet vendor is named, no source list is enumerated, and no integration method or effort is described.

Nothing published states where Drug Diversion Intelligence runs or where its data rests. Imprivata's trust page speaks for the whole portfolio, describing protection of customer data across product use in the cloud and on premises and referring to cloud service enhancements, without saying which applies to this product, and no provider, region or residency commitment is stated.

Canadian availability was announced as a distinct market entry in March 2023, and whether Canadian customer data stays in Canada is not stated. The product stores controlled substance data for three years, and nothing says where that archive sits.

No price or basis of charge is published for Drug Diversion Intelligence. Imprivata publishes its contract paper on its legal page, including a master license and services agreement with a FairWarning product schedule and a managed services agreement, which shows the product is licensed with optional managed services.

Nothing published states what drives the cost, whether per bed, per facility or per monitored user, or whether the Drug Diversion Monitoring Services team is included, priced separately or sold as a tier. That is the difference between buying software and buying an outsourced monitoring function, and it stays unknown until a sales conversation.

Coverage is described by lifecycle stage rather than by care setting, spanning prescription, dispensing, preparation, administration, waste and removal, with departments identified as higher risk singled out for monitoring and electronic prescribing workflows included in scope. Geographic coverage is documented across the United States and Canada with a dated market entry for the latter.

What is missing is the setting level breakdown a buyer needs: nothing distinguishes acute inpatient from procedural, anesthesia, retail, ambulatory or post acute deployment, and no facility count or segment profile is published.